(ANAB) AnaptysBio - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0327241065

Stock: Rosnilimab, ANB032, ANB033, ANB101, Imsidolimab

Total Rating 42
Risk 30
Buy Signal 0.49
Biotechnology » Biotechnology
Age: 9y
Market Cap: 1,305m
Avg Trading Vol: 17.9M USD
ATR: 5.92%
Peers RS (IBD): 82.00

EPS (Earnings per Share)

EPS (Earnings per Share) of ANAB over the last years for every Quarter: "2020-12": 1.2, "2021-03": -0.66, "2021-06": -0.02, "2021-09": -0.24, "2021-12": -1.13, "2022-03": -1.31, "2022-06": -1.15, "2022-09": -1.18, "2022-12": -0.93, "2023-03": -1.58, "2023-06": -1.5, "2023-09": -1.41, "2023-12": -1.59, "2024-03": -1.64, "2024-06": -1.71, "2024-09": -1.14, "2024-12": -0.72, "2025-03": -1.28, "2025-06": -1.34, "2025-09": 0.52, "2025-12": 0,
EPS CAGR: 39.39%
EPS Trend: 52.5%
Last SUE: -1.11
Qual. Beats: 0

Revenue

Revenue of ANAB over the last years for every Quarter: 2020-12: 60, 2021-03: 11.247, 2021-06: 30.027, 2021-09: 20.89, 2021-12: 1.010999, 2022-03: 0.97, 2022-06: 1.216, 2022-09: 1.293, 2022-12: 6.808, 2023-03: 1.374, 2023-06: 3.46, 2023-09: 3.318, 2023-12: 9.005, 2024-03: 7.179, 2024-06: 10.971, 2024-09: 30.017, 2024-12: 43.113, 2025-03: 27.771, 2025-06: 22.263, 2025-09: 76.32, 2025-12: null,
Rev. CAGR: 216.79%
Rev. Trend: 94.1%
Last SUE: 3.71
Qual. Beats: 1
Risk 5d forecast
Volatility 70.7%
Relative Tail Risk -21.6%
Reward TTM
Sharpe Ratio 1.72
Alpha 181.43
Character TTM
Beta 0.468
Beta Downside 0.255
Drawdowns 3y
Max DD 69.32%
CAGR/Max DD 0.33

Description: ANAB AnaptysBio December 25, 2025

AnaptysBio, Inc. (NASDAQ: ANAB) is a clinical-stage biotech focused on immunology therapeutics, developing a portfolio of antibody programs that modulate T-cell activity and innate immune pathways.

Key pipeline assets include Rosnilimab (PD-1+ T-cell agonist/depletor), ANB032 (BTLA checkpoint inhibitor), ANB033 (anti-CD122 antagonist), ANB101 (BDCA2 modulator for plasmacytoid dendritic cells), and Imsidolimab (IL-36 receptor blocker) which is currently in Phase 3 for generalized pustular psoriasis.

The company’s strategic collaboration with GlaxoSmithKline provides an upfront payment of roughly $150 million and milestone potential exceeding $500 million, bolstering its cash position to about $150 million as of Q3 2025-sufficient for roughly 18 months of runway under current burn rates.

Sector-wide, immunology remains a high-growth segment, with global biologics sales projected to exceed $400 billion by 2028, driven by rising prevalence of autoimmune diseases and increasing payer acceptance of targeted therapies.

For a deeper quantitative view of ANAB’s valuation dynamics, you might explore ValueRay’s analytical tools.

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income: -84.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.41 > 0.02 and ΔFCF/TA -20.20 > 1.0
NWC/Revenue: 172.6% < 20% (prev 708.0%; Δ -535.4% < -1%)
CFO/TA -0.41 > 3% & CFO -145.0m > Net Income -84.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.68 > 1.5 & < 3
Outstanding Shares: last quarter (29.0m) vs 12m ago 0.43% < -2%
Gross Margin: 9.72% > 18% (prev -1.71%; Δ 1142 % > 0.5%)
Asset Turnover: 40.04% > 50% (prev 11.59%; Δ 28.45% > 0%)
Interest Coverage Ratio: -0.09 > 6 (EBITDA TTM -4.57m / Interest Expense TTM 77.6m)

Altman Z'' -4.52

A: 0.83 (Total Current Assets 330.6m - Total Current Liabilities 38.1m) / Total Assets 353.1m
B: -2.33 (Retained Earnings -822.2m / Total Assets 353.1m)
C: -0.02 (EBIT TTM -6.99m / Avg Total Assets 423.3m)
D: -2.15 (Book Value of Equity -822.1m / Total Liabilities 382.5m)
Altman-Z'' Score: -4.52 = D

Beneish M -0.90

DSRI: 2.09 (Receivables 75.7m/12.2m, Revenue 169.5m/57.2m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.39 (AQ_t 0.02 / AQ_t-1 0.06)
SGI: 2.96 (Revenue 169.5m / 57.2m)
TATA: 0.17 (NI -84.6m - CFO -145.0m) / TA 353.1m)
Beneish M-Score: -0.90 (Cap -4..+1) = D

What is the price of ANAB shares?

As of February 07, 2026, the stock is trading at USD 47.90 with a total of 594,943 shares traded.
Over the past week, the price has changed by +0.10%, over one month by +10.88%, over three months by +33.06% and over the past year by +198.26%.

Is ANAB a buy, sell or hold?

AnaptysBio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy ANAB.
  • StrongBuy: 7
  • Buy: 3
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ANAB price?

Issuer Target Up/Down from current
Wallstreet Target Price 67.9 41.8%
Analysts Target Price 67.9 41.8%
ValueRay Target Price 51.4 7.4%

ANAB Fundamental Data Overview January 31, 2026

P/S = 7.6978
P/B = 114.7281
Revenue TTM = 169.5m USD
EBIT TTM = -6.99m USD
EBITDA TTM = -4.57m USD
Long Term Debt = 14.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.04m USD (from shortTermDebt, last quarter)
Debt = 346.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 236.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.40b USD (1.30b + Debt 346.4m - CCE 249.0m)
Interest Coverage Ratio = -0.09 (Ebit TTM -6.99m / Interest Expense TTM 77.6m)
EV/FCF = -9.65x (Enterprise Value 1.40b / FCF TTM -145.3m)
FCF Yield = -10.37% (FCF TTM -145.3m / Enterprise Value 1.40b)
FCF Margin = -85.75% (FCF TTM -145.3m / Revenue TTM 169.5m)
Net Margin = -49.94% (Net Income TTM -84.6m / Revenue TTM 169.5m)
Gross Margin = 9.72% ((Revenue TTM 169.5m - Cost of Revenue TTM 153.0m) / Revenue TTM)
Gross Margin QoQ = 58.85% (prev -69.90%)
Tobins Q-Ratio = 3.97 (Enterprise Value 1.40b / Total Assets 353.1m)
Interest Expense / Debt = 6.50% (Interest Expense 22.5m / Debt 346.4m)
Taxrate = 0.0% (0.0 / 15.1m)
NOPAT = -6.99m (EBIT -6.99m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 8.68 (Total Current Assets 330.6m / Total Current Liabilities 38.1m)
Debt / Equity = -11.78 (negative equity) (Debt 346.4m / totalStockholderEquity, last quarter -29.4m)
Debt / EBITDA = -51.78 (negative EBITDA) (Net Debt 236.6m / EBITDA -4.57m)
Debt / FCF = -1.63 (negative FCF - burning cash) (Net Debt 236.6m / FCF TTM -145.3m)
Total Stockholder Equity = 7.68m (last 4 quarters mean from totalStockholderEquity)
RoA = -19.99% (Net Income -84.6m / Total Assets 353.1m)
RoE = -1101 % (out of range, set to none) (Net Income TTM -84.6m / Total Stockholder Equity 7.68m)
RoCE = -31.35% (EBIT -6.99m / Capital Employed (Equity 7.68m + L.T.Debt 14.6m))
RoIC = -90.93% (negative operating profit) (NOPAT -6.99m / Invested Capital 7.68m)
WACC = 7.40% (E(1.30b)/V(1.65b) * Re(7.64%) + D(346.4m)/V(1.65b) * Rd(6.50%) * (1-Tc(0.0)))
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 4.47%
Fair Price DCF = unknown (Cash Flow -145.3m)
EPS Correlation: 52.51 | EPS CAGR: 39.39% | SUE: -1.11 | # QB: 0
Revenue Correlation: 94.08 | Revenue CAGR: 216.8% | SUE: 3.71 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-1.11 | Chg30d=-0.033 | Revisions Net=-1 | Analysts=8
EPS next Year (2026-12-31): EPS=-4.10 | Chg30d=-0.051 | Revisions Net=-1 | Growth EPS=-183.6% | Growth Revenue=-41.2%

Additional Sources for ANAB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle